Efficacy and safety of low-dose rosuvastatin/ezetimibe for dyslipidemia in patients with rheumatoid arthritis or osteoarthritis
The efficacy and safety of low-dose rosuvastatin/ezetimibe in reducing LDL-C levels were similar between the RA and OA groups. Baseline LDL-C level was the sole independent factor associated with LDL-C reduction, irrespective of inflammatory status.
Authors
- Seung‐Jae Hong (ORCID: https://orcid.org/0000-0002-9803-529X)
- Kyung‐Ann Lee (ORCID: https://orcid.org/0000-0001-7499-6363)
- Sang-Hyon Kim (ORCID: https://orcid.org/0000-0002-8030-7939)
- Sung-Soo Kim (ORCID: https://orcid.org/0000-0002-8556-343X)
- Hyun‐Sook Kim (ORCID: https://orcid.org/0000-0001-9213-7140)
- Seong-Hyeok Bak
Institutions
- Soonchunhyang University Hospital Seoul (KR)
- Kyung Hee University Medical Center (KR)
- Keimyung University Dongsan Medical Center (KR)
- Gangneung Asan Hospital (KR)
- Keimyung University (KR)
Publication Details
- Journal
- Medicine
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1097/md.0000000000043133
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.01